Rubicon Research and Avantor have teamed up to develop a gastro-retentive excipient for pharmaceutical applications.
Specific details of the project have not been disclosed, although the general idea is to combine Mumbai, India-based Rubicon’s delivery technology with Avantor’s manufacturing and marketing capacity. The firms plan to launch the product next year.
Rubicon CEO Pratibha Pilgaonkar said: “This material will provide solutions to the global pharmaceutical industry for molecules with challenging therapeutic requirements, either from the pipelines of innovator companies or for life cycle management opportunities for already marketed products.”
The firm did not respond to requests for additional information ahead of publication.